Cure My Disease

Don't miss your cure!

 Log in / Sign up

Which SGLT2 inhibitor wins? trial pits empagliflozin against dapagliflozin

NCT ID NCT06642272

Disease control Sponsor: Herlev and Gentofte Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 18, 2026 · Last updated Sep 18, 2026

Summary

Researchers compare empagliflozin and dapagliflozin, two similar diabetes drugs, to see which works better at preventing death, heart problems, and kidney damage in adults with type 2 diabetes, heart failure, or chronic kidney disease. The trial uses electronic health records to randomly assign patients to one drug or the other based on the time of day they receive care. About 17,200 patients will take part. The goal is to learn which drug offers better protection for the heart and kidneys.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
empagliflozin and dapagliflozin, two SGLT2 inhibitor drugs
What this could lead to
If one drug proves more effective, doctors could choose it first for patients with these conditions, potentially preventing hospitalizations and kidney decline.
What could go wrong
The trial may find no meaningful difference between the two drugs, or results may not apply to all patient groups. Both drugs carry known risks like genital infections and rare ketoacidosis.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 17,200 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2024

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged 18 years or more Exclusion Criteria: * Incapabability of giving informed consent * Withdrawal of informed consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic kidney diseases are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic kidney disease chronic renal failure syndrome heart failure type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic kidney diseases Diabetes mellitus type 2 Heart failure

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    12 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Bispebjerg Hospital

    RECRUITING

    Copenhagen, Denmark

  • Bornholms Hospital

    RECRUITING

    Rønne, Denmark

  • Herlev and Gentofte Hospital

    RECRUITING

    Herlev, Denmark

  • Holbæk Sygehus

    RECRUITING

    Holbæk, Denmark

  • Hvidovre Hospital

    RECRUITING

    Hvidovre, Denmark

  • Nordsjællands Hospital

    RECRUITING

    Hillerød, Denmark

  • Nykøbing F. Sygehus

    RECRUITING

    Nykøbing Falster, Denmark

  • Rigshospitalet

    RECRUITING

    Copenhagen, Denmark

  • Sjællands Universitetshospital

    RECRUITING

    Køge, Denmark

  • Sjællands Universitetshospital

    RECRUITING

    Roskilde, Denmark

  • Slagelse Sygehus

    RECRUITING

    Slagelse, Denmark

  • Steno Diabetes Center Copenhagen

    RECRUITING

    Herlev, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.